You Should Know These Things About Jazz Pharmaceuticals plc (JAZZ)


As of Wednesday close, Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) stock was down -$1.95, moving down -1.27 percent to $151.26. The average number of shares traded per day over the past five days has been 453,200 shares. 5 times new highs have been achieved over the past 5 days, with a $8.52 gain in that time frame. In the last twenty days, the average volume was 549,685, while in the previous 50 days, it was 545,990.

Since last month, JAZZ stock rose 9.91%. Shares of the company fell to $133.47 on 10/24/22, the lowest level in the past month. A 52-week high of $169.98 was reached on 04/07/22 after having rallying from a 52-week low of $117.64. Since the beginning of this year, JAZZ’s stock price has risen by 18.73% or $23.86, and marked a new high 14 times. However, the stock has declined by -11.01% since its 52-week high.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


JAZZ stock investors should be aware that Jazz Pharmaceuticals plc (JAZZ) stock had its last reported insider trading activity 8 days ago on Nov 16. Patil Neena M, the EVP & Chief Legal Officer of the company, disposed of 3,510 shares for $142.34 on Nov 16. It resulted in a $499,613 divestment by the insider. Larkin Finbar sold 197 shares at an average price of $149.33 on Nov 14. The insider now owns 19,409 shares following the transaction. On Nov 10, Chairman & CEO COZADD BRUCE C sold 2,000 shares at $150.00 apiece. The transaction was valued at $300,000.

Valuation Metrics

The stock’s beta is 0.75. Besides these, the trailing price-to-sales (P/S) ratio of 2.62, the price-to-book (PB) ratio of 3.46, and the price-to-cash flow ratio of 8.71 may also be considered.

Financial Health

In the three months ended June 29, Jazz Pharmaceuticals plc’s quick ratio stood at 2.30, while its current ratio was 3.20, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 2.07, and the total debt-to-equity ratio was 2.09. On the profitability front, the trailing twelve-month gross margin is 85.80% percent. In the year ended June 29, operating margins totaled 6.90%. Based on annual data, JAZZ earned $2.65 billion in gross profit and brought in $3.09 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -0.50%. Return on equity (ROE) for the past 12 months was -0.60%.

In Jazz Pharmaceuticals plc’s quarter-end financial report for June 29, it reported total debt of $5.7 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. JAZZ’s revenue rose 38.16% to $932.88 million during the quarter, while net income inched up to $940.65 million. While analysts expected Jazz Pharmaceuticals plc to report $4.19 quarterly earnings, the actual figure was $4.3 per share, beating the consensus estimate by 2.60%. During the quarter, the company generated $173.59 million in EBITDA. The liabilities of Jazz Pharmaceuticals plc were 7.64 billion at the end of its most recent quarter ended June 29, and its total debt was $6.11 billion. The value of shareholders’ equity is $62.97 million.

Technical Picture

This quick technical analysis looks at Jazz Pharmaceuticals plc’s (JAZZ) price momentum. With a historical volatility rate of 29.76%, the RSI 9-day stood at 61.91% on 23 November.

With respect to its five-day moving average, the current Jazz Pharmaceuticals plc price is up by +5.97% percent or $8.52. At present, JAZZ shares trade +8.52% above its 20-day simple moving average and -5.49% percent below its 100-day simple moving average. However, the stock is currently trading approximately -0.37% below its SMA50 and +8.33% above its SMA200.

Stochastic coefficient K was 70.60% and Stochastic coefficient D was 59.92%, while ATR was 4.75. Given the Stochastic reading of 71.34% for the 14-day period, the RSI (14) reading has been calculated as 60.17%. As of today, the MACD Oscillator reading stands at 2.84, while the 14-day reading stands at 4.05.

Analyst Ratings

UBS launched its rating on Jazz Pharmaceuticals plc (NASDAQ: JAZZ) to a Buy in a note to investors on June 14, 2022. Jazz Pharmaceuticals plc (JAZZ) has been rated Buy by analysts. According to 0 brokerage firms, JAZZ is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Jazz Pharmaceuticals plc stock as buy, with 14 recommending it as overweight.

With a median target price of $200.00, the current consensus forecast for the stock is $180.00 – $240.00. Based on these forecasts, analysts predict Jazz Pharmaceuticals plc (JAZZ) will achieve an average price target of $201.82.


Please enter your comment!
Please enter your name here